Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

CD22 Competitive Landscape Report 2016: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics - Research and Markets

Research and Markets
Posted on: 28 Nov 16

Research and Markets has announced the addition of the "CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics" report to their offering.

This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodgkin lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively.

CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.

Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results, indicating the need for more effective payloads but, at the same time, also providing development opportunities for new treatment modalities such as:

- Combination therapies;

- Radioimmunotherapy (RIT);

- Immunotoxins (IT);

- Antibody-Drug Conjugates (ADC); and Chimeric Antigen Receptor (CAR) T-Cells.

This report describes the profiles of 16 different specific and bispecific anti-CD22 immunotherapeutics based on different treatment modalities. The most advanced molecules have been submitted for regulatory approval. Furthermore, the profiles of nine companies active in the development of anti-CD22 immunotherapeutics are presented.

This report describes and analyzes the:

- Target Background & Scientific Rationale

- Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

- Competitive Landscape

- Profiles of Anti-CD22 Immunotherapeutics

- Profiles of Companies with CD22-Targeted Immunotherapeutics

Key Topics Covered:

1. Target Background & Scientific Rationale

2. Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

3. Competitive Landscape

4. Profiles of Anti-CD22 Immunotherapeutics:

- Naked antibodies;

- Radioimmunotherapy (RIT);

- Immunotoxins (IT);

- Antibody-Drug Conjugates (ADC); and Chimeric Antigen Receptor (CAR) T-Cells.

5. Profiles of Companies with CD22-Targeted Immunotherapeutics

References

ADDENDUM: Competitor Analysis of CD22-Targeted Immunotherapeutics

For more information about this report visit http://www.researchandmarkets.com/research/nj5scb/cd22_a_suitable.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161128006083/en/

Business Wire
www.businesswire.com

Last updated on: 28/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.